RxDoctor Payments Data

Steven Allen, MD

Family Medicine · Millbrook, ALNPI 1508814922

Payments from drug & device makers

$1,115in general payments, 2019–2025

Across 60 payments — averaging $18.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$383
  • Mylan Specialty L.p.$104
  • Astellas Pharma US Inc$80
  • Boehringer Ingelheim$70
  • AstraZeneca$48
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$45
  • plus $385 from 16 others

What the payments were for

  • Food & beverage$1,03593%
  • Education$807%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,115 in reported general payments places this provider in the 55th percentile of 1,680 family medicine providers in Alabama.

See all family medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$59,135
Medicare patients
244
Services billed
4,283

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter59$53,996
MounjaroTirzepatide43$53,644
JardianceEmpagliflozin48$50,826
OzempicSemaglutide38$38,943
FarxigaDapagliflozin Propanediol26$29,736
EliquisApixaban35$28,093
VraylarCariprazine Hcl15$26,876
RybelsusSemaglutide11$24,476
RexultiBrexpiprazole13$24,115
JanuviaSitagliptin Phosphate24$17,678
TrulicityDulaglutide13$12,661
TradjentaLinagliptin16$12,209
Breo ElliptaFluticasone/Vilanterol17$10,452
Spiriva RespimatTiotropium Bromide12$6,352
Gabapentin377$6,279

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat$70$69,38776 claims
Lilly USA, LLCMounjaro, Trulicity$29$66,30556 claims
GSKTrelegy Ellipta, Breo Ellipta$40$64,44876 claims
Novo NordiskOzempic, Rybelsus$14$63,41949 claims
PfizerEliquis, Premarin$33$31,33948 claims
AbbVieVraylar, Synthroid$383$30,59046 claims
AstraZenecaFarxiga$48$29,73626 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,680 family medicine providers in Alabama.

Other family medicine in Millbrook

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →